# Autologous Stem Cell Transplantation for Crohn's Disease

> **NCT00692939** · PHASE1,PHASE2 · RECRUITING · sponsor: **Paul Szabolcs** · enrollment: 20 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** autologous CD34-selected peripheral blood stem cells transplant
- **DRUG:** Alemtuzumab
- **DRUG:** ATG
- **DRUG:** Melphalan
- **DRUG:** Thiotepa
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** G-CSF
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT00692939
- **Lead sponsor:** Paul Szabolcs
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2012-06-26
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00692939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00692939, "Autologous Stem Cell Transplantation for Crohn's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00692939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*